Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Sanderling Ventures is a venture capital firm founded in 1979 and based in the United States. The firm has supported over 90 biomedical companies, focusing on early-stage financing and active management. Sanderling Ventures emphasizes close partnerships with entrepreneurs to drive significant growth.
Sanderling Ventures invests in early-stage biomedical companies, including small molecule therapeutics, biologics, vaccines, drug delivery, platform technologies, and medical devices. The firm provides seed and early-stage funding, along with management leadership, technical and regulatory expertise, and cost-control strategies.
Notable companies in Sanderling Ventures' portfolio include: Actimis - Acquired by Boehringer Ingelheim; Aderis - Acquired by Schwarz Pharma; Advanced Cardiovascular - Acquired by Guidant Corp. (now Boston Scientific); Altor BioScience - Acquired by ImmunityBio, Inc.; CalciMedica - Listed on NASDAQ (CALC); Chimerix - Listed on NASDAQ (CMRX); Dendreon - Listed on NASDAQ (DNDN); Dynavax - Listed on NASDAQ (DVAX); Regeneron - Listed on NASDAQ (REGN).
Submit your pitch through their website's contact form.
Yes, Sanderling Ventures often leads investment rounds in the companies they support, particularly in the early stages.
The firm is committed to long-term partnerships and typically participates in follow-on investments to support the growth of its portfolio companies.
Specific fund size details are not disclosed, but the firm has a history of supporting over 90 biomedical companies since its inception.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.